Recent 8-K filings for UTHR

• August 5, 2026, 6:33 AM ET earnings materiality 0.70 neutral item 2.02item 9.01

  United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M

  Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.

• July 23, 2026, 7:00 AM ET leadership materiality 0.30 neutral item 5.02item 7.01item 9.01

  United Therapeutics appoints Victor Dzau to Board of Directors

  Board expanded to 13 members; Victor Dzau, M.D., appointed effective July 22, 2026.

• June 29, 2026, 4:32 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  United Therapeutics shareholders approve 2026 Stock Incentive Plan with 1.5M new shares

  Plan adds 1,500,000 new shares; total reserve includes 2,413,730 carryover from prior plan plus returning shares.

• May 6, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback

  Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.

• March 30, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)

  TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×2

  United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi

  Board approves up to $2B stock repurchase program through March 9, 2027.

• March 2, 2026, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening

  Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

  FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.

• January 22, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02item 5.03item 7.01item 9.01 ◈ Governance Changes

  United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold

  Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.

• October 29, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

  Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.

• September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

  TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).

• August 1, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  United Therapeutics enters $1B accelerated share repurchase agreements with Citibank

  Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

  Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.

• June 27, 2025, 7:59 PM ET other material materiality 0.45 neutral item 5.02item 5.07item 9.01

  Shareholders approve amended 2015 Stock Incentive Plan; increase share reserve by 950k shares and extend plan to 2035

  Shareholders approved amendment to 2015 Stock Incentive Plan, increasing share reserve by 950,000 shares to 14,770,000 total.

• April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

  Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).

• April 28, 2025, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 1.02item 2.03item 9.01 ◈ Debt Financings

  United Therapeutics enters $2.5B revolving credit facility, repays $200M of existing debt

  New $2.5B unsecured revolving credit facility, with option to increase by up to $750M.

• February 26, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

  Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.

• January 13, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  United Therapeutics presents at J.P. Morgan Healthcare Conference; no specific financials disclosed in filing

  Presentation slides filed as Exhibit 99.1 but full content not provided in the filing text.

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

  Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

  Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.

• June 27, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 5.07item 7.01item 9.01

  United Therapeutics shareholders elect Jan Malcolm to board, approve stock plan amendment adding 1.32M shares

  Jan Malcolm, former Minnesota Health Commissioner, elected to board; replaces Prof. Katherine Klein who did not stand for re-election.

• May 1, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

  Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.

• March 29, 2024, 7:59 PM ET debt materiality 0.35 neutral item 1.01item 2.03 ◈ Material Agreements

  United Therapeutics extends credit facility maturity to March 31, 2029

  Second one-year extension of $1.2B and $800M revolving credit facilities.

• March 25, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  United Therapeutics authorizes $1B accelerated share repurchase with Citibank

  Board authorized up to $1B of common stock repurchase; ASR agreement signed with Citibank.

• February 27, 2024, 6:59 PM ET litigation materiality 0.75 neutral item 8.01

  United Therapeutics moves to block Liquidia's PH-ILD product with preliminary injunction and FDA suit

  Filed preliminary injunction motion in Delaware on Feb 26, 2024, alleging Liquidia's PH-ILD product infringes U.S. Patent No. 11,826,327 (expires 2042).

• February 21, 2024, 6:59 PM ET other material materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment

  FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).

• December 20, 2023, 6:59 PM ET litigation materiality 0.85 negative item 8.01

  Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner

  Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.

• November 29, 2023, 6:59 PM ET other material materiality 0.40 neutral item 8.01

  United Therapeutics extends Adcirca license with Lilly through Dec 2026

  Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.

• November 1, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M

  Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.

• August 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)

  Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.

• July 24, 2023, 7:59 PM ET litigation materiality 0.75 positive item 8.01item 9.01

  United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed

  Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.

• July 14, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07

  United Therapeutics Board sets annual say-on-pay frequency until 2029

  Board determined annual say-on-pay frequency, consistent with 2023 shareholder vote.

• June 28, 2023, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×5

  United Therapeutics shareholders approve stock plan amendment increasing shares by 1M, extend plan to 2033

  Shareholders approved amendment to 2015 Stock Incentive Plan, increasing authorized shares by 1,000,000 and extending plan to April 20, 2033.

• May 3, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%

  Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.

• April 21, 2023, 7:59 PM ET other materiality 0.25 neutral item 5.03item 9.01 ◈ Governance Changes

  United Therapeutics amends bylaws to enhance stockholder proposal and nomination procedures

  Amendments require additional background info on proposing stockholders and nominees, and representation on solicitation intentions.

• March 31, 2023, 7:59 PM ET debt materiality 0.20 neutral item 1.01item 2.03 ◈ Material Agreements

  United Therapeutics extends credit facility maturity to March 31, 2028

  Extended maturity of $1.2B and $800M unsecured revolving credit facilities by one year to March 31, 2028.

• February 22, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67

  Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).

• January 9, 2023, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  United Therapeutics presents at J.P. Morgan Healthcare Conference; no material updates in filing exhibit

  Company presented business overview at 41st annual J.P. Morgan Healthcare Conference on Jan 9, 2023.

• November 2, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)

  Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.

• October 11, 2022, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF

  First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).

• September 20, 2022, 7:59 PM ET other material materiality 0.65 negative item 8.01

  United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD

  DSMC recommended termination after routine safety and efficacy analysis.

• September 1, 2022, 7:59 PM ET litigation materiality 0.90 positive item 8.01item 9.01

  Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027

  District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.

• August 3, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%

  Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.

• June 28, 2022, 7:59 PM ET other material materiality 0.30 neutral item 5.02item 5.07item 9.01

  Shareholders approve 500,000-share increase and extension of 2015 Stock Incentive Plan to 2032

  Plan share reserve increased by 500,000 to 11.5M shares; expiration extended to April 25, 2032.

• May 24, 2022, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA approves United Therapeutics' Tyvaso DPI for PAH and PH-ILD; launch underway

  FDA approved Tyvaso DPI (treprostinil inhalation powder) for PAH (WHO Group 1) and PH-ILD (WHO Group 3).

• May 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY

  Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.

• April 22, 2022, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

  CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022

  CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.

• April 1, 2022, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 1.02item 2.03item 9.01

  United Therapeutics enters $2B credit agreement, draws $800M to refinance existing debt

  New $2B unsecured revolving credit facility with $1.2B Tranche A and $800M Tranche B; can be increased by up to $500M.

• February 24, 2022, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022

  Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.

• January 18, 2022, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  FDA accepts United Therapeutics' resubmitted NDA for Tyvaso DPI as Class 1 review; target date Feb 2022

  FDA accepted resubmission of NDA for Tyvaso DPI as a Class 1 response after Complete Response Letter in Oct 2021.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

26 positive 3 negative 21 neutral

source · UTHR on sec.gov